Tracers / [68Ga]CE-21
[68Ga]CE-21
Also written as [Ga-68]Ga-CE-21
- Radionuclide
- Ga-68 t½ 67.71 min
- Modality
- Therapy
- Production route
- —
- Stage
- first-in-human
- Syntheses indexed
- 1
What it is
- Compound class
- CEA-targeted nanobody conjugated with NOTA chelator (CE-21-NOTA)
- Target / mechanism
- Carcinoembryonic antigen (CEA) PMID 41275230
- Clinical application
- PET/CT imaging of CEA-expressing tumors PMID 41275230
- Theranostic pair
- <a href="/tracers/lu177-ce21/">lu177-ce21</a>
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | SPE | 43.6 ± 3.9% | >99% | CEA-Nanobody (CE-21-NOTA conjugate) | 41275230 2025 J Nanobiotechnology A solution of ⁶⁸Ga in 1 mL of 0.05 M HCl was mixed with 0.3 mL of 0.25 M sodium acetate buffer to adjust the pH to approximately 5.0, followed by the addition of 200 µg of CEA-Nanobody. — radiochemical yields (RCY) of 43.6 ± 3.9% for [⁶⁸Ga]Ga-CE-21 and 39.6 ± 2.9% for [⁶⁸Ga]Ga-CE-88, with radiochemical purities (RCP) > 99% |
Need this precursor?We can point you to suppliers for [68Ga]CE-21, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 41275230. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 41275230: 'CEA-Nanobody (CE-21-NOTA conjugate)'. Stage set/updated at stage 23 from PMID 41275230: 'A high-affinity CEA-targeted nanobody for 68Ga PET imaging and 177Lu-based radioisotope therapy: preclinical and first-in-human evaluation.'.